NASDAQ:UPB
Upstream Bio, Inc.
Upstream Bio, Inc.'s revenue grew 20.4% in fiscal 2025 to $2.9M while operating margin fell to −5618.8%, its lowest in 3 years. Free cash flow was −$133.4M, −4675.5% of revenue, and the diluted share count rose 293.6%.Summary generated from Upstream Bio, Inc.'s SEC filings. Latest annual report filed Mar 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$2.9M
Revenue growth+20.4%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−5618.8%
Net margin−5026.0%
ROICn/a
Return on equity−35.4%
Debt / equityn/a
Free cash flow−$133.4M
FCF margin−4675.5%
Share count change+293.6%
Financials
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 2 | 2 | 3 |
| Operating income | −40 | −78 | −160 |
| Net income | −21 | −63 | −143 |
| Free cash flow | −38 | −60 | −133 |
Recent filings
- 4Insider transaction report
Sep 17, 2026 - 4Insider transaction report
Sep 17, 2026 - 8-KRegulation FD disclosure
Sep 1, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 8-KResults of operations and financial condition
Aug 11, 2026 - 8-KResults of a shareholder vote
Jun 10, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 13, 2026 - 8-KResults of operations and financial condition
May 13, 2026